Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
PARSIPPANY, N.J., Feb. 22, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2017 financial results before the open of the U.S. markets on Wednesday February 28, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 5198726. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 5198726. The replay of the call will be available for one week from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
